ClinicalTrials.Veeva
Menu

Find clinical trials for Glioblastoma (GBM) in Montréal, QC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Glioblastoma
Recurrence
Brain Cancer
Glioma
Cancer
Astrocytoma
Gliosarcoma

Glioblastoma (GBM) trials near Montréal, QC, CAN:

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/II....

Enrolling
Glioblastoma
Drug: Temozolomide
Radiation: Radiation

Phase 2, Phase 3

Global Coalition for Adaptive Research

Montréal, Quebec, Canada and 61 other locations

To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM...

Active, not recruiting
Glioblastoma Multiforme
Device: Optune®
NovoCure
NovoCure

Montréal, Quebec, Canada and 132 other locations

(TNBC), ovarian cancer, gastric cancer, colorectal cancer (CRC), glioblastoma (GBM), biliary tract cancers (BTC), or pancreatic can...

Active, not recruiting
Glioblastoma
Gastric Cancer
Biological: Pembrolizumab
Drug: Lenvatinib

Phase 2

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Montreal, Quebec, Canada and 87 other locations

progression-free survival (PFS) of patients with newly diagnosed glioblastoma multiforme (GBM) can be improved by the addition of i...

Active, not recruiting
Glioblastoma
Procedure: Standard surgery
Drug: Temozolomide

Phase 3

Universitätsmedizin Mannheim

Montréal, Quebec, Canada and 18 other locations

To assess:* efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification...

Enrolling
Glioblastoma Multiforme
Brain Tumor
Drug: APL-101 Oral Capsules

Phase 2

Apollomics

Montreal, Quebec, Canada and 90 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems